{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:35:08Z","timestamp":1787769308696,"version":"build-2784847793"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,3,21]],"date-time":"2015-03-21T00:00:00Z","timestamp":1426896000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s40263-015-0239-x","type":"journal-article","created":{"date-parts":[[2015,3,20]],"date-time":"2015-03-20T07:26:23Z","timestamp":1426836383000},"page":"277-291","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["Statin Treatment in Multiple Sclerosis: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"29","author":[{"given":"Gorm","family":"Pihl-Jensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tsakiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jette Lautrup","family":"Frederiksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,21]]},"reference":[{"key":"239_CR1","doi-asserted-by":"crossref","unstructured":"Atkins GJ, Amor S, Fletcher J. The biology of multiple sclerosis. Cambridge: Cambridge University Press; 2012.","DOI":"10.1017\/CBO9780511979088"},{"key":"239_CR2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1067\/mhj.2003.70","volume":"145","author":"LT Clark","year":"2003","unstructured":"Clark LT. Treating dyslipidemia with statins: the risk-benefit profile. Am Heart J. 2003;145:387\u201396.","journal-title":"Am Heart J."},{"key":"239_CR3","doi-asserted-by":"crossref","unstructured":"Abramson JD, Rosenberg HG, Jewell N, Wright JM. Should people at low risk of cardiovascular disease take a statin? BMJ. 2013;347(f6123).","DOI":"10.1136\/bmj.f6123"},{"issue":"10","key":"239_CR4","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJM199509073331003","volume":"333","author":"JA Kobashigawa","year":"1995","unstructured":"Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995;333(10):621\u20137.","journal-title":"N Engl J Med"},{"issue":"12","key":"239_CR5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1126\/stke.112pt3","volume":"1","author":"S Waiczies","year":"2008","unstructured":"Waiczies S, Bendix I, Zipp F. Geranylation but not GTP-loading of Rho GTPases determines T cell function. Sci Signal. 2008;1(12):3.","journal-title":"Sci Signal"},{"issue":"2","key":"239_CR6","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nrn2059","volume":"8","author":"JA Allen","year":"2007","unstructured":"Allen JA, Halverson-Tamboli RA, Rasenick MM. Lipid raft microdomains and neurotransmitter signalling. Nat Rev Neurosci. 2007;8(2):128\u201340 Epub 2006\/12\/30.","journal-title":"Nat Rev Neurosci"},{"key":"239_CR7","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1002\/eji.200636567","volume":"36","author":"R Ghittoni","year":"2006","unstructured":"Ghittoni R, Napolitani G, Benati D, Uliveri C, Patrussi L, et al. Simvastatin inhibits MHC class II pathway of antigen presentation by impairing Ras superfamily GTPases. Eur J Immnuol. 2006;36:2885\u201393.","journal-title":"Eur J Immnuol"},{"key":"239_CR8","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/89058","volume":"6","author":"G Weitz-Schmidt","year":"2001","unstructured":"Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 2001;6:687\u201392.","journal-title":"Nat Med."},{"issue":"6911","key":"239_CR9","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nature01158","volume":"420","author":"S Youssef","year":"2002","unstructured":"Youssef S, St\u00fcve O, Patarroyo JC, Ruiz PJ, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002;420(6911):78\u201384.","journal-title":"Nature"},{"issue":"2","key":"239_CR10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/jnr.1207","volume":"66","author":"R Stanislaus","year":"2001","unstructured":"Stanislaus R, Singh AK, Singh I. Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental autoimmune encephalomyelitis. J Neurosci Res. 2001;66(2):155\u201362.","journal-title":"J Neurosci Res."},{"issue":"8","key":"239_CR11","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1096\/fj.02-1014fje","volume":"17","author":"J Greenwood","year":"2003","unstructured":"Greenwood J, Walters CE, Pryce G, Kanuga N, Beraud E, Baker D, et al. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J. 2003;17(8):905\u20137 Epub 2003 Mar 5. FASEB J. 2003;17(8):905\u20137.","journal-title":"FASEB J."},{"issue":"2","key":"239_CR12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0304-3940(99)00414-0","volume":"269","author":"R Stanislaus","year":"1999","unstructured":"Stanislaus R, Pahan K, Singh AK, Singh I. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by lovastatin. Neurosci Lett. 1999;269(2):71\u20134.","journal-title":"Neurosci Lett."},{"issue":"4","key":"239_CR13","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1172\/JCI25805","volume":"116","author":"O St\u00fcve","year":"2006","unstructured":"St\u00fcve O, Youssef S, Weber MS, Nessler S, von B\u00fcdingen HC, Hemmer B, et al. Immunomodulatory synergy by combination of atorvastatin and glatirameracetate in treatment of CNS autoimmunity. J Clin Invest. 2006;116(4):1037\u201344.","journal-title":"J Clin Invest."},{"issue":"1","key":"239_CR14","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jneuroim.2006.06.005","volume":"178","author":"X Peng","year":"2006","unstructured":"Peng X, Jin J, Giri S, Montes M, et al. Immunomodulatory effects of 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors, potential therapy for relapsing remitting multiple sclerosis. J Neuroimmunol. 2006;178(1):130\u20139.","journal-title":"J Neuroimmunol."},{"key":"239_CR15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0021-9150(00)00417-2","volume":"153","author":"MT Montero","year":"2000","unstructured":"Montero MT, Hernandez O, Suarez Y, et al. Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells. Atherosclerosis. 2000;153:303.","journal-title":"Atherosclerosis."},{"issue":"1","key":"239_CR16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.atherosclerosis.2003.10.002","volume":"172","author":"A Yilmaz","year":"2004","unstructured":"Yilmaz A, Reiss C, Tantawi O, et al. HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis. 2004;172(1):85\u201393.","journal-title":"Atherosclerosis."},{"issue":"8","key":"239_CR17","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1002\/eji.200838189","volume":"38","author":"JL Sun","year":"2008","unstructured":"Sun JL, Hongwei Q, et al. The IFN-\u03b3-induced transcriptional program of the CIITA gene is inhibited by statins. Eur J Immnuol. 2008;38(8):2325\u201336.","journal-title":"Eur J Immnuol."},{"key":"239_CR18","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/emm.2002.63","volume":"34","author":"HK Chung","year":"2002","unstructured":"Chung HK, Lee IK, Kang H, et al. Statin inhibits interferongamma-induced expression of intercellular adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells. Exp Mol Med. 2002;34:451\u201361.","journal-title":"Exp Mol Med."},{"issue":"9","key":"239_CR19","doi-asserted-by":"crossref","first-page":"5630","DOI":"10.4049\/jimmunol.174.9.5630","volume":"174","author":"S Waiczies","year":"2005","unstructured":"Waiczies S, Prozorovski T, Infante-Duarte C, Hahner A, Aktas O, Ullrich O, et al. Atorvastatin induces T cell anergy via phosphorylation of ERK1. J Immunol. 2005;174(9):5630\u20135.","journal-title":"J Immunol."},{"issue":"1","key":"239_CR20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/ana.20875","volume":"60","author":"I Ifergan","year":"2006","unstructured":"Ifergan I, Wosik K, Cayrol R, et al. Statins reduce human blood-brain-barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. Ann Neurol. 2006;60(1):45\u201355.","journal-title":"Ann Neurol"},{"issue":"2","key":"239_CR21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/glia.20269","volume":"53","author":"HF Kuipers","year":"2006","unstructured":"Kuipers HF, Rappert AA, Mommaas AM, et al. Simvastatin affects cell motility and actin cytoskeleton distribution of microglia. Glia. 2006;53(2):115\u201323.","journal-title":"Glia"},{"issue":"10","key":"239_CR22","doi-asserted-by":"crossref","first-page":"6988","DOI":"10.4049\/jimmunol.180.10.6988","volume":"180","author":"X Zhang","year":"2008","unstructured":"Zhang X, Jin J, Peng X, Ramgolam VS, Markovic-Plese S. Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J Immunol. 2008;180(10):6988\u201396.","journal-title":"J Immunol."},{"key":"239_CR23","unstructured":"Dhawan N, Reder AT. Statins block interferon signaling in human immune cells: potential loss of the therapeutic effect of IFN-B in multiple sclerosis. Neurology. 2007;68(Suppl 1: A364)."},{"key":"239_CR24","doi-asserted-by":"crossref","unstructured":"Kieseier BC, Archelos JJ, Hartung HP. Different eff ects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases. Arch Neurol. 2004;61(929\u201332).","DOI":"10.1001\/archneur.61.6.929"},{"key":"239_CR25","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/STROKEAHA.107.498923","volume":"39","author":"J Ponce","year":"2008","unstructured":"Ponce J, de la Ossa NP, Hurtado O, Millan M, Arenillas JF, et al. Simvastatin reduces the association of NMDA receptors to lipid rafts: a cholesterol-mediated effect in neuroprotection. Stroke. 2008;39:1269\u201375.","journal-title":"Stroke."},{"key":"239_CR26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1089\/neu.2007.0369","volume":"25","author":"HLD Wu","year":"2008","unstructured":"Wu HLD, Jiang H, Xiong Y, Qu C, et al. Simvastatin-mediated upregulation of VEGF and BDNF, activation of the PI3K\/Akt pathway, and increase of neurogenesis are associated with therapeutic improvement after traumatic brain injury. J Neurotrauma. 2008;25:130\u20139.","journal-title":"J Neurotrauma."},{"key":"239_CR27","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1161\/01.ATV.0000142813.33538.82","volume":"24","author":"S Wolfrum","year":"2004","unstructured":"Wolfrum S, Dendorfer A, Rikitake Y, Stalker TJ, et al. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase\/protein kinase Akt and cardiovascular protection. Thromb Vasc Biol. 2004;24:1842\u20137.","journal-title":"Thromb Vasc Biol."},{"issue":"1","key":"239_CR28","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.expneurol.2004.12.010","volume":"193","author":"MB S\u00e4ttler","year":"2005","unstructured":"S\u00e4ttler MB, Diem R, Merkler D, et al. Simvastatin treatment does not protect retinal ganglion cells from degeneration in a rat model of autoimmune optic neuritis. Exp Neurol. 2005;193(1):163\u201371.","journal-title":"Exp Neurol."},{"key":"239_CR29","doi-asserted-by":"crossref","unstructured":"Morishita S, Oku H, Horie T, Tonari M, Kida T, Okubo A, et al. Systemic simvastatin rescues retinal ganglion cells from optic nerve injury possibly through suppression of astroglial NF-kappaB activation. PloS one. 2014;9(1):e84387 (Epub 2014\/01\/07).","DOI":"10.1371\/journal.pone.0084387"},{"issue":"1","key":"239_CR30","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.pneurobio.2009.02.002","volume":"88","author":"PJ Most van der","year":"2009","unstructured":"van der Most PJ, Dolga AM, Nijholt IM, et al. Statins: mechanisms of neuroprotection. Prog Neurobiol. 2009;88(1):64\u201375.","journal-title":"Prog Neurobiol."},{"key":"239_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/glia.20422","volume":"55","author":"P Marz","year":"2007","unstructured":"Marz P, Otten U, Miserez AR. Statins induce differentiation and cell death in neurons and astroglia. Glia. 2007;55:1\u201312.","journal-title":"Glia."},{"issue":"9","key":"239_CR32","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1002\/glia.22537","volume":"61","author":"AS Paintlia","year":"2013","unstructured":"Paintlia AS, Paintlia MK, Singh AK, Singh I. Modulation of Rho-Rocksignaling pathway protects oligodendrocytes against cytokine toxicity via PPAR-dependent mechanism. Glia. 2013;61(9):1500\u201317.","journal-title":"Glia."},{"issue":"2","key":"239_CR33","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/glia.20441","volume":"55","author":"VE Miron","year":"2007","unstructured":"Miron VE, Rajasekharan S, Jarjour AA, Zamvil SS, Kennedy TE, Antel JP. Simvastatin regulates oligodendroglial process dynamics and survival. Glia. 2007;55(2):130\u201343.","journal-title":"Glia."},{"issue":"3","key":"239_CR34","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410130302","volume":"13","author":"CM Poser","year":"1983","unstructured":"Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13(3):227\u201331 Epub 1983\/03\/01.","journal-title":"Ann Neurol"},{"issue":"1","key":"239_CR35","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","volume":"50","author":"WI McDonald","year":"2001","unstructured":"McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121\u20137 Epub 2001\/07\/18.","journal-title":"Ann Neurol"},{"issue":"2","key":"239_CR36","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292\u2013302 Epub 2011\/03\/10.","journal-title":"Ann Neurol"},{"key":"239_CR37","unstructured":"The Cochrane Collaboration\u2019s tool for assessing risk of bias. In: Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. Updated March 2011. Available from http:\/\/handbook.cochrane.org\/ ."},{"issue":"7","key":"239_CR38","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1177\/1352458508091368","volume":"14","author":"J Sellner","year":"2008","unstructured":"Sellner J, Greeve I, Mattle HP. Atorvastatin decreases high-sensitivity C-reactive protein in multiple sclerosis. Mult Scler. 2008;14(7):981\u20134.","journal-title":"Mult Scler."},{"issue":"18","key":"239_CR39","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1212\/01.wnl.0000319698.40024.1c","volume":"71","author":"G Birnbaum","year":"2008","unstructured":"Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology. 2008;71(18):1390\u20135.","journal-title":"Neurology."},{"issue":"4","key":"239_CR40","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1177\/1352458509358909","volume":"16","author":"R Lanzillo","year":"2010","unstructured":"Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, Ventrella G, et al. Atorvastatin combined to interferon to verify the efficacy (ACTIVE)in relapsing\u2013remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. Mult Scler. 2010;16(4):450\u20134.","journal-title":"Mult Scler."},{"issue":"7","key":"239_CR41","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1177\/1352458510369147","volume":"16","author":"M Togha","year":"2010","unstructured":"Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, et al. Simvastatin treatment in patients with relapsing\u2013remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial. Mult Scler. 2010;16(7):848\u201354.","journal-title":"Mult Scler."},{"key":"239_CR42","doi-asserted-by":"crossref","unstructured":"Sorensen PS, Lycke J, Er\u00e4linna JP, Edland A, Wu X, Frederiksen JL , et al. For the SIMCOMBIN study investigators. Simvastatin as add-on therapy to interferon beta-1a for relapsing\u2013remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. Lancet Neurol. 2011;10(8):691\u2013701.","DOI":"10.1016\/S1474-4422(11)70144-2"},{"issue":"11","key":"239_CR43","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1007\/s00415-012-6513-7","volume":"259","author":"CP Kamm","year":"2012","unstructured":"Kamm CP, El-Koussy M, Humpert S, Findling O, von Bredow F, Burren Y, et al. Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled trial. J Neurol. 2012;259(11):2401\u201313.","journal-title":"J Neurol."},{"issue":"1","key":"239_CR44","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/1352458511415452","volume":"18","author":"A Tsakiri","year":"2012","unstructured":"Tsakiri A, Kallenbach K, Fugl\u00f8 D, Frederiksen J, et al. Simvastatin improves final visual outcome in acute optic neuritis: a randomized study. Mult Scler. 2012;18(1):72\u201381.","journal-title":"Mult Scler."},{"issue":"1","key":"239_CR45","doi-asserted-by":"crossref","first-page":"e86663","DOI":"10.1371\/journal.pone.0086663","volume":"9","author":"CP Kamm","year":"2014","unstructured":"Kamm CP, El-Koussy M, Humpert S, Findling O, et al. Atorvastatin added to interferon beta for relapsing multiple sclerosis: 12-month treatment extension of the randomized multicenter SWABIMS trial. PLoS One. 2014;9(1):e86663.","journal-title":"PLoS One"},{"key":"239_CR46","doi-asserted-by":"crossref","unstructured":"Chataway J, Schuerer N, Alsanousi A, Chan D et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet. 2014;383(9936):2213\u201321.","DOI":"10.1016\/S0140-6736(13)62242-4"},{"issue":"15","key":"239_CR47","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1212\/WNL.0b013e31824f7fdd","volume":"75","author":"E Waubant","year":"2012","unstructured":"Waubant E, Pelletier D, Mass M, Cohen JA, Kita M, Cross A. Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study. Neurology. 2012;75(15):1171\u20138.","journal-title":"Neurology."},{"issue":"6","key":"239_CR48","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1007\/s00415-003-1070-8","volume":"250","author":"A Sena","year":"2003","unstructured":"Sena A, Pedrosa R, Gra\u00e7a Morais M. Therapeutic potential of lovastatin in multiple sclerosis. J Neurol. 2003;250(6):754\u20135.","journal-title":"J Neurol."},{"issue":"9421","key":"239_CR49","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(04)16205-3","volume":"363","author":"T Vollmer","year":"2004","unstructured":"Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet. 2004;363(9421):1607\u20138.","journal-title":"Lancet."},{"issue":"4","key":"239_CR50","doi-asserted-by":"crossref","first-page":"e1928","DOI":"10.1371\/journal.pone.0001928","volume":"3","author":"F Paul","year":"2008","unstructured":"Paul F, Waiczies S, Wuerfel J, Bellmann-Strobl J, D\u00f6rr J, Waiczies H, et al. Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PloS one. 2008;3(4):e1928.","journal-title":"PloS one."},{"issue":"3","key":"239_CR51","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/1352458511421920","volume":"18","author":"MM Paz Sold\u00e1n","year":"2012","unstructured":"Paz Sold\u00e1n MM, Pittock SJ, Weigand SD, Yawn BP, Rodriguez M. Statin therapy and multiple sclerosis disability in a population based cohort. Mult Scler. 2012;18(3):358\u201363.","journal-title":"Mult Scler"},{"issue":"23","key":"239_CR52","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1212\/WNL.0b013e3181a92b96","volume":"72","author":"RA Rudick","year":"2009","unstructured":"Rudick RA, Pace A, Rani MR, Hyde R, Panzara M, Appachi S, et al. Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a. Neurology. 2009;72(23):1989\u201393.","journal-title":"Neurology."},{"key":"239_CR53","unstructured":"Laplaud D, Lefrefre F, Auffray-Calvier E, Nguyen JM, Edan G, Le Page E, et al. Safety, tolerance and efficacy of Pravastatine in MS-STEP in multiple sclerosis: a randomized double-blind placebo controlled pilot study. Poster 457. ECTRIMS 2008."},{"key":"239_CR54","unstructured":"\u00d6ztekin N, \u00d6ztekin F, Munis \u00d6. Atorvastatin combined with interfereon beta 1a in relapsing remitting multiple sclerosis: preliminary results of a 24 month randomized open-label clinical trial. Poster 485. ECTRIMS 2008."},{"key":"239_CR55","unstructured":"Brescia Morra V, Alfano B, Lanzillo R, Quarantelli M, Comerci M, Marini S, et al. Efficacy, safety and tolerability of atorvastatin in patients with relapsing-remitting multiple sclerosis in treatment with interferon-beta (ARIANNA): a mutlicentre, randomised, double-blind, placebo-controlled, parallel-group-study. Poster 477. ECTRIMS 2012."},{"key":"239_CR56","unstructured":"Markovic-Plese S, Speer D, Jin J, Chen Y, Smrtka J, Ingram L, et al. Statin and intramuscular interferon beta-1a combination therapy is safe and well tolerated in patients with clinically isolated syndrome suggestive of multiple sclerosis, a pilot study. Poster 232A. ECTRIMS 2007."},{"key":"239_CR57","unstructured":"Qiang XH, Qi ZL. Characteristic study on chinese patients with multiple sclerosis. 2014. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00818103 . Accessed 1 Dec 2014."},{"key":"239_CR58","unstructured":"Riser E. A Safety study of combination treatment with avonex and zocor in relapsing remitting multiple sclerosis. 2014. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00818103 . Cited 1 Dec 2014."},{"issue":"13 Pt 2","key":"239_CR59","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1212\/01.wnl.0000285426.73143.f7","volume":"70","author":"Y Zhao","year":"2008","unstructured":"Zhao Y, Traboulsee A, Petkau AJ, Li D. Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis. Neurology. 2008;70(13 Pt 2):1092\u20137 Epub 2007\/11\/16.","journal-title":"Neurology"},{"key":"239_CR60","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1189\/jlb.0904510","volume":"77","author":"HK Takahashi","year":"2005","unstructured":"Takahashi HK, Mori S, Iwagaki H, et al. Differential effect of LFA703, pravastatin, and fluvastatin on production of IL-18 and expression of ICAM-1 and CD40 in human monocytes. J Leukoc Biol. 2005;77:400\u20137.","journal-title":"J Leukoc Biol."},{"key":"239_CR61","doi-asserted-by":"crossref","unstructured":"Feng X, Han D, Kilaru BK, Franek BS, Niewold TB et al. Inhibition of interferon-beta responses in multiple sclerosis immune cells associated with highdose statins. Arch Neurol. 2012;69:1303\u20139.","DOI":"10.1001\/archneurol.2012.465"},{"key":"239_CR62","unstructured":"Tsakiri A, Frederiksen J. Simvastatin as an add-on treatment to copaxone for the treatment of relapsing multiple sclerosis. WITHDRAWN. 2014. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00429442?term=simvastatin+copaxone&rank=1 . Cited 1 Dec 2014."},{"key":"239_CR63","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1212\/01.WNL.0000036271.49066.06","volume":"59","author":"E Fisher","year":"2002","unstructured":"Fisher E, Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology. 2002;59:1412\u201320.","journal-title":"Neurology."},{"key":"239_CR64","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1212\/WNL.0b013e3181d6b125","volume":"74","author":"RA Marrie","year":"2010","unstructured":"Marrie RA, Rudick R, Horwitz R, Cutter G, Tyry T, Campagnolo D, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology. 2010;74:1041\u20137.","journal-title":"Neurology."},{"issue":"13","key":"239_CR65","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1212\/01.wnl.0000257815.20548.df","volume":"68","author":"AL Jefferson","year":"2007","unstructured":"Jefferson AL, Massaro JM, Wolf PA, et al. Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study. Neurology. 2007;68(13):1032\u20138.","journal-title":"Neurology."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-015-0239-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-015-0239-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-015-0239-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T01:17:20Z","timestamp":1566436640000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-015-0239-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,21]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["239"],"URL":"https:\/\/doi.org\/10.1007\/s40263-015-0239-x","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,21]]}}}